Opinion

Video

LEAP Study: Lenvatinib Plus Pembrolizumab in Patients With RCC and Brain Metastasis

Author(s):

Benjamin Garmezy, MD,Martin H. Voss, MD

Chandler H. Park, MD, discusses the LEAP study investigating lenvatinib plus pembrolizumab in patients with renal cell carcinoma with brain metastasis.

Related Videos
David Rimm, MD, PhD
James J. Harding, MD, associate attending physician, Memorial Sloan Kettering Cancer Center
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Diane Reidy-Lagunes, MD, vice chair, Oncology Operations, Regional Care Network, Memorial Sloan Kettering Cancer Center
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
David Rimm, MD, PhD, discusses current HER2 immunohistochemistry assays that are used in the management of breast cancer, and their shortcomings.
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Related Content
ALLO-316 in Advanced CD70-Positive ccRCC | Image Credit: © Cornflakesei - stock.adobe.com
November 27th 2024

ALLO-316 Demonstrates Early Activity and Safety in Advanced CD70-Positive ccRCC

Oncology Unplugged
November 6th 2024

Review Key Genitourinary Cancer Data From the 2024 ESMO Congress With Chandler Park, MD

James J. Harding, MD, of Memorial Sloan Kettering Cancer Center
November 21st 2024

Ongoing Research Could Help Define the Role of Immunotherapy in Earlier-Stage HCC

Francine Foss, MD, professor, medicine (hematology) and dermatology, director, Multidisciplinary T Cell Lymphoma Program, Yale School of Medicine; scientific leader, Lymphoma CRT, Yale Cancer Center
October 17th 2024

FDA Approval Insights: Denileukin Diftitox in Relapsed/Refractory CTCL

David A. Braun, MD, PhD
November 9th 2024

Post Hoc Analysis Reveals Potential Serum Glycoproteomic Biomarkers for Nivolumab/Cabozantinib in Advanced RCC

PD-L1, KIM-1 Expression in ccRCC | Image Credit: © Cornflakesei - stock.adobe.com
November 8th 2024

PD-L1, KIM-1 Expression Are Predictive of Outcomes With Adjuvant Nivolumab Alone, Plus Ipilimumab in ccRCC